Posters

Mucoepidermoid carcinoma of conjunctiva: a rare variant of squamous cell carcinoma

Poster Details

First Author: R.Rajagopal INDIA

Co Author(s):    G. Iyer   K. Kumar   V. Norona   M. Pauly   B. Mukherjee  

Abstract Details

Purpose:

Review risk factors and clinical features of 2 patients who presented with recurrent aggressive ocular surface squamous neoplasia confirmed as mucoepidermoid carcinoma of conjunctiva by histopathology

Setting:

Medical Research Foundation, Sankara Nethralaya, 18 College Road, Chennai, Tamil Nadu, India

Methods:

Retrospective review of case records of 2 patients with histopathology proven mucoepidermoid carcinoma referred to a tertiary care centre following primary excision elsewhere. Both patients required globe sacrificing procedures for globe infiltration.

Results:

Patients were 64 and 32 years of age. Both patients had undergone primary excision elsewhere (1 patient had one excision and the other had three excision biopsies) followed by topical mitomycin postoperatively. Histopathology was suggestive of squamous cell carcinoma Both were referred for aggressive recurrences Recurrence was in the form of nodular infiltration. Patients were seronegative for HIV. Metastatic workup was negative. Systemic evaluation was unremarkable. Radio-imaging confirmed globe infiltration. Globe sacrificing procedures included extended enucleation and exenteration. In view of the unusually aggressive recurrent and recalcitrant nature of the lesions, histopathology slides were specifically reviewed for mucoepidemoid variant of squamous cell carcinoma and the same was confirmed

Conclusions:

Mucoepidermoid variant of squamous cell carcinoma is a rare entity and is locally invasive. In the absence of systemic predisposing factors like HIV / Xeroderma pigmentosa / immunosuppression, histopathological samples of patients who present with aggressive and infiltrative lesions /early recurrences should include review of slides for mucoepidermoid variant of squamous cell carcinoma. FINANCIAL INTEREST: NONE